Martingale Asset Management L P Sells 600 Shares of Regeneron Pharmaceuticals Inc (REGN)
Martingale Asset Management L P lessened its holdings in shares of Regeneron Pharmaceuticals Inc (NASDAQ:REGN) by 49.9% in the fourth quarter, HoldingsChannel reports. The firm owned 603 shares of the biopharmaceutical company’s stock after selling 600 shares during the period. Martingale Asset Management L P’s holdings in Regeneron Pharmaceuticals were worth $227,000 as of its most recent SEC filing.
Other institutional investors and hedge funds have also recently bought and sold shares of the company. Steward Partners Investment Advisory LLC boosted its holdings in Regeneron Pharmaceuticals by 495.2% during the 4th quarter. Steward Partners Investment Advisory LLC now owns 369 shares of the biopharmaceutical company’s stock worth $138,000 after acquiring an additional 307 shares during the last quarter. Advisory Services Network LLC boosted its holdings in Regeneron Pharmaceuticals by 147.0% during the 4th quarter. Advisory Services Network LLC now owns 447 shares of the biopharmaceutical company’s stock worth $168,000 after acquiring an additional 266 shares during the last quarter. Vident Investment Advisory LLC purchased a new position in Regeneron Pharmaceuticals during the 3rd quarter worth $200,000. AE Wealth Management LLC purchased a new position in Regeneron Pharmaceuticals during the 4th quarter worth $206,000. Finally, Moors & Cabot Inc. purchased a new position in Regeneron Pharmaceuticals during the 3rd quarter worth $217,000. 65.62% of the stock is currently owned by hedge funds and other institutional investors.
A number of equities analysts have issued reports on REGN shares. Piper Jaffray Companies reaffirmed a “buy” rating and set a $540.00 price objective on shares of Regeneron Pharmaceuticals in a report on Monday, November 13th. Zacks Investment Research raised shares of Regeneron Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Tuesday, November 14th. Evercore ISI cut their price objective on shares of Regeneron Pharmaceuticals from $605.00 to $445.00 and set an “outperform” rating on the stock in a report on Thursday, November 16th. BTIG Research reaffirmed a “buy” rating and set a $520.00 price objective on shares of Regeneron Pharmaceuticals in a report on Wednesday, November 22nd. Finally, BMO Capital Markets set a $444.00 price objective on shares of Regeneron Pharmaceuticals and gave the stock a “hold” rating in a report on Monday, November 27th. Four investment analysts have rated the stock with a sell rating, fifteen have issued a hold rating, ten have assigned a buy rating and one has issued a strong buy rating to the company’s stock. Regeneron Pharmaceuticals currently has a consensus rating of “Hold” and an average price target of $450.65.
Shares of Regeneron Pharmaceuticals Inc (REGN) opened at $341.70 on Friday. The company has a market cap of $36,799.72, a PE ratio of 33.11, a price-to-earnings-growth ratio of 1.07 and a beta of 1.54. Regeneron Pharmaceuticals Inc has a fifty-two week low of $313.53 and a fifty-two week high of $543.55. The company has a current ratio of 3.82, a quick ratio of 3.18 and a debt-to-equity ratio of 0.11.
Regeneron Pharmaceuticals (NASDAQ:REGN) last released its quarterly earnings data on Thursday, February 8th. The biopharmaceutical company reported $5.23 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $4.18 by $1.05. The business had revenue of $1.58 billion for the quarter, compared to the consensus estimate of $1.50 billion. Regeneron Pharmaceuticals had a net margin of 20.41% and a return on equity of 28.48%. The company’s revenue was up 28.9% compared to the same quarter last year. During the same period in the prior year, the firm earned $3.04 earnings per share. equities research analysts anticipate that Regeneron Pharmaceuticals Inc will post 19.2 EPS for the current year.
TRADEMARK VIOLATION NOTICE: This report was reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this report on another site, it was copied illegally and republished in violation of United States and international copyright legislation. The legal version of this report can be viewed at https://www.thecerbatgem.com/2018/03/11/martingale-asset-management-l-p-sells-600-shares-of-regeneron-pharmaceuticals-inc-regn.html.
Regeneron Pharmaceuticals Profile
Regeneron Pharmaceuticals, Inc is a biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. The Company commercializes medicines for eye diseases, high low-density lipoprotein (LDL) cholesterol, and an inflammatory condition and have product candidates in development in other areas, including rheumatoid arthritis, asthma, atopic dermatitis, pain, cancer, and infectious diseases.
Want to see what other hedge funds are holding REGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Regeneron Pharmaceuticals Inc (NASDAQ:REGN).
Receive News & Ratings for Regeneron Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.